<DOC>
	<DOCNO>NCT01444547</DOCNO>
	<brief_summary>The purpose study evaluate efficacy safety first-line chemotherapy cisplatin paclitaxel esophageal cancer</brief_summary>
	<brief_title>A Study Predictive Value ERCC1 Esophageal Cancer Patients Treated With Paclitaxel Cisplatin</brief_title>
	<detailed_description>Open label single arm phase II study cisplatin paclitaxel patient recurrent metastatic esophageal cancer . 92 Patients enrol local trial . The primary objective study determine response rate treatment.Schedule study follow : paclitaxel 150 mg/m2 administer intravenous infusion 3 hour Days 1 , follow cisplatin 50 mg/m2 Days 2 . This study also include investigation ERCC1 expression order ass determinant efficacy treatment cisplatin paclitaxel study population .</detailed_description>
	<mesh_term>Esophageal Neoplasms</mesh_term>
	<mesh_term>Paclitaxel</mesh_term>
	<mesh_term>Albumin-Bound Paclitaxel</mesh_term>
	<mesh_term>Cisplatin</mesh_term>
	<criteria>Histologically proven diagnosis squamous cell carcinoma adenocarcinoma esophagus locally advanced , recurrent metastatic disease Performance Status 02 Eastern Cooperative Oncology Group ( ECOG ) performance status Scale Previous adjuvant preoperative chemotherapy without contain paclitaxel platinum least 12 month enrollment Adequate organ function include follow : Bone marrow : absolute neutrophil count ( ANC ) &gt; equal 1.5 * 109/L , platelet &gt; equal 100 *109/L , hemoglobin &gt; equal 10 g/dL . Hepatic : bilirubin &lt; equal 1.5 x ULN ; alkaline phosphatase , aspartate transaminase ( AST ) alanine transaminase ( ALT ) &lt; equal 3 x ULN ( alkaline phosphatase , AST , ALT minor equal 5 x ULN acceptable liver tumor involvement ) , serum albumin &gt; equal to3g/dL . Renal : Calculated creatinine clearance major equal 60 ml/min ( use standard CockcroftGault formula ) . No Prior palliative chemotherapy advance disease Previous radiation therapy allow limited must include whole pelvis radiation . Patients must recover toxic effect treatment prior study enrollment ( except alopecia ) . Prior radiotherapy must complete least 30 day study enrollment Known suspect brain metastasis Second primary malignancy</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>70 Years</maximum_age>
	<verification_date>May 2014</verification_date>
	<keyword>esophageal cancer</keyword>
	<keyword>paclitaxel</keyword>
	<keyword>cisplatin</keyword>
</DOC>